Targeting PI3K/AKT/mTOR network for treatment of leukemia. (Q38364871)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

review article

1 reference

title

Targeting PI3K/AKT/mTOR network for treatment of leukemia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Nazanin Heidari

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Laura Mediani

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Silvano Capitani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Ahmad Ahmadzadeh

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Najmaldin Saki

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Mohammad Shahjahani

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

25 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

Cellular and Molecular Life Sciences

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

72

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

2337-2347

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00018-015-1867-5

1 March 2020

exact match

0 references

cites work

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The emerging mechanisms of isoform-specific PI3K signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

AKT/PKB signaling: navigating downstream

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Modulation of Akt and ERK1/2 pathways by resveratrol in chronic myelogenous leukemia (CML) cells results in the downregulation of Hsp70

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Adult acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

FLT-3: a new focus in the understanding of acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Forced expression of the DEK-NUP214 fusion protein promotes proliferation dependent on upregulation of mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Effect of CAL-101, a PI3Kδ inhibitor, on ribosomal rna synthesis and cell proliferation in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Proliferation of PTEN-deficient haematopoietic tumour cells is not affected by isoform-selective inhibition of p110 PI3-kinase and requires blockade of all class 1 PI3K activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

mTOR regulates cell survival after etoposide treatment in primary AML cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The physiology and pathophysiology of rapamycin resistance: implications for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Genomic landscapes and clonality of de novo AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Disruption of the PI3K/AKT/mTOR signaling cascade and induction of apoptosis in HL-60 cells by an essential oil from Monarda citriodora

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

"Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The roles of miR-146a in the differentiation of Jurkat T-lymphoblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Introduction: the history of arsenic trioxide in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Tanshinone IIA induces autophagic cell death via activation of AMPK and ERK and inhibition of mTOR and p70 S6K in KBM-5 leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

MicroRNA expression profiles classify human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Chemical Inhibitors and microRNAs (miRNA) Targeting the Mammalian Target of Rapamycin (mTOR) Pathway: Potential for Novel Anticancer Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Micro RNAs as a new therapeutic target towards leukaemia signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

MiR-223 suppresses cell proliferation by targeting IGF-1R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

Antileukemic effects of AMPK activators on BCR-ABL-expressing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00018-015-1867-5

From pathogenesis to treatment of chronic lymphocytic leukaemia

21 January 2018

1 reference

12 December 2020

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.

1 reference

12 December 2020

Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells

1 reference

12 December 2020

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

1 reference

12 December 2020

Caveolin-1 plays a key role in the oleanolic acid-induced apoptosis of HL-60 cells

1 reference

12 December 2020

Treatment of acute promyelocytic leukemia

1 reference

12 December 2020

1 reference

12 December 2020

L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway

1 reference

12 December 2020

10.1007/S00018-015-1867-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25712020%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1 reference